Cirsium Biosciences highlighted five cardiac gene therapy trials, including Lexeo Therapeutics, AskBio, Solid Biosciences, Sardocor, and Tenaya Therapeutics.
Public source
Publisher name
Public post
Gene therapies for cardiac disease have been heating up recently. Here are 5 of them that you should know about. (Save this for later) NOTE: These are ranked in no parti…
Company
Cirsium Biosciences
Democratizing gene therapy through transformative manufacturing methods
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 11–50 employees
About Cirsium Biosciences
Democratizing gene therapy through transformative manufacturing methods
See moreLatest activity
Latest activity from Cirsium Biosciences
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
AskBio Inc.
AskBio Inc. presented baseline participant characteristics from the Phase 2 GenePHIT trial at the ESC Congress.
Research & Knowledge
BridgeBio
BridgeBio published a new publication in the American Heart Association's Journal of the American Heart Association regarding the joint assessment of sTTR and NT-proBNP for ATTRCM.
Research & Knowledge
Fortrea
Fortrea published results from an early-stage trial showing that a single-dose experimental gene-editing therapy reduced bad cholesterol and triglycerides in patients for at least one year.
Research & Knowledge
Affinia Therapeutics
Affinia Therapeutics is recruiting participants for an upcoming clinical trial at the Montreal Heart Institute for cardiomyopathy associated with the BAG3 gene.
Research & Knowledge
Imbria Pharmaceuticals